×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
UNCY – unicycive therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
UNCY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
07:00 am
uncy
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
Low
Report
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
11/13
07:15 am
uncy
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
11/12
08:33 am
uncy
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
High
Report
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
11/11
07:00 am
uncy
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
High
Report
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
10/28
07:06 am
uncy
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 [Yahoo! Finance]
High
Report
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 [Yahoo! Finance]
10/28
07:03 am
uncy
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
High
Report
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
10/16
04:35 pm
uncy
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
High
Report
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
10/16
12:03 pm
uncy
Results of Phase I trial shed positive light on UNI-494 for acute kidney injury [Yahoo! Finance]
Low
Report
Results of Phase I trial shed positive light on UNI-494 for acute kidney injury [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
06:02 am
uncy
Form EFFECT Unicycive Therapeutics,
Low
Report
Form EFFECT Unicycive Therapeutics,
11/15
06:17 am
uncy
Form EFFECT Unicycive Therapeutics,
Low
Report
Form EFFECT Unicycive Therapeutics,
11/14
07:14 pm
uncy
Form SC 13G/A Unicycive Therapeutics, Filed by: Logos Global Management LP
Low
Report
Form SC 13G/A Unicycive Therapeutics, Filed by: Logos Global Management LP
11/14
07:01 pm
uncy
Form SC 13G/A Unicycive Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.
Low
Report
Form SC 13G/A Unicycive Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.
11/14
05:46 pm
uncy
Form SC 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Low
Report
Form SC 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
11/14
05:05 pm
uncy
Form SC 13G/A Unicycive Therapeutics, Filed by: GREAT POINT PARTNERS LLC
Low
Report
Form SC 13G/A Unicycive Therapeutics, Filed by: GREAT POINT PARTNERS LLC
11/14
04:56 pm
uncy
Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: Nantahala Capital Management, LLC
Low
Report
Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: Nantahala Capital Management, LLC
11/14
04:56 pm
uncy
Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: Nantahala Capital Partners Limited Partnership
Low
Report
Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: Nantahala Capital Partners Limited Partnership
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: